Vitality Biopharma (OTCMKTS:VBIO) and Eloxx Pharmaceuticals (OTCMKTS:ELOX) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, risk, earnings, valuation, institutional ownership and dividends.

Earnings & Valuation

This table compares Vitality Biopharma and Eloxx Pharmaceuticals’ revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Vitality Biopharma $100,000.00 399.85 -$4.30 million N/A N/A
Eloxx Pharmaceuticals N/A N/A N/A N/A N/A

Eloxx Pharmaceuticals has lower revenue, but higher earnings than Vitality Biopharma.

Analyst Recommendations

This is a summary of current recommendations and price targets for Vitality Biopharma and Eloxx Pharmaceuticals, as provided by

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Vitality Biopharma 0 0 0 0 N/A
Eloxx Pharmaceuticals 0 0 4 0 3.00

Eloxx Pharmaceuticals has a consensus price target of $25.25, indicating a potential upside of 102.65%. Given Eloxx Pharmaceuticals’ higher possible upside, analysts clearly believe Eloxx Pharmaceuticals is more favorable than Vitality Biopharma.


This table compares Vitality Biopharma and Eloxx Pharmaceuticals’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Vitality Biopharma -4,355.14% -3,389.09% -719.69%
Eloxx Pharmaceuticals N/A N/A N/A

Insider and Institutional Ownership

0.3% of Vitality Biopharma shares are owned by institutional investors. 8.7% of Vitality Biopharma shares are owned by insiders. Comparatively, 44.0% of Eloxx Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.


Eloxx Pharmaceuticals beats Vitality Biopharma on 6 of the 8 factors compared between the two stocks.

About Vitality Biopharma

Vitality Biopharma, Inc. engages in the development of cannabinoid pharmaceuticals for the treatment of neurological and inflammatory disorders in the United States. The company's products in pipeline include VBX-100, an oral cannabinoid formulation for inflammatory bowel disease, C.difficile-associated diarrhea and colitis, and narcotic bowel syndrome; and VBX-210, a cannabinoid formulation, which is in preclinical studies for the treatment of gastrointestinal conditions. It develops additional cannabinoid product formulations for refractory pain and autism spectrum disorder. The company was formerly known as Stevia First Corp. and changed its name to Vitality Biopharma, Inc. in July 2016. The company was founded in 2007 and is based in Los Angeles, California.

About Eloxx Pharmaceuticals

Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics for the treatment of rare and ultra-rare premature stop codon diseases. Its lead program is ELX-02, which is in Phase I clinical trial, which focuses on the treatment of cystic fibrosis and cystinosis patients with diagnosed nonsense mutations. The company was founded in 2013 and is headquartered in Waltham, Massachusetts.

Receive News & Ratings for Vitality Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vitality Biopharma and related companies with's FREE daily email newsletter.